About NeuroKaire
NeuroKaire is a company based in Kearny (United States) founded in 2017 by Talia Cohen Solal and Daphna Laifenfeld. NeuroKaire has raised $20 million across 6 funding rounds from investors including European Union, GreyBird Ventures and Meron Capital. NeuroKaire offers products and services including AI Precision Platform and Drug Development Service. NeuroKaire operates in a competitive market with competitors including Manus Neuro, Luciole Medical, Rhaeos, RetiSpec and Brain.Space, among others.
- Headquarter Kearny, United States
- Founders Talia Cohen Solal, Daphna Laifenfeld
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genetikaplus Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20 M (USD)
in 6 rounds
-
Latest Funding Round
$10 M (USD), Series A
Dec 17, 2024
-
Investors
European Union
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NeuroKaire
NeuroKaire offers a comprehensive portfolio of products and services, including AI Precision Platform and Drug Development Service.
Uses AI and stem-cells for personalized psychiatry treatment predictions.
Analyzes patient-derived neurons for bio-pharma drug efficacy testing.
People of NeuroKaire
Unlock access to complete
Sales and Marketing
2 people
Leadership Team
1 people
COO Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of NeuroKaire
NeuroKaire has successfully raised a total of $20M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NeuroKaire
NeuroKaire has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Union, GreyBird Ventures and Meron Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on precision diagnostic technologies.
|
Locked | Locked | Locked | |
|
Meron Capital is focused on investing in technology sectors.
|
Locked | Locked | Locked | |
|
No company activity is described on the website.
|
Locked | Locked | Locked |
Investor details for NeuroKaire
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NeuroKaire
Investment portfolio details for NeuroKaire
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NeuroKaire
Detailed financials for NeuroKaire
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurokaire Comparisons
Peer comparison for NeuroKaire
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeuroKaire
NeuroKaire operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Manus Neuro, Luciole Medical, Rhaeos, RetiSpec and Brain.Space, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Devices for neuromotor impairment biomarkers are provided.
|
|
| Locked | Locked | Locked |
Brain monitoring devices and analytics platforms are developed and provided.
|
|
| Locked | Locked | Locked |
Noninvasive device developed for CSF monitoring and hydrocephalus management.
|
|
| Locked | Locked | Locked |
Non-invasive eye scanner for early Alzheimer’s detection is developed.
|
|
| Locked | Locked | Locked |
Brain activity data is analyzed digitally for medical providers.
|
Detailed competitors of NeuroKaire
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurokaire
Complete news archive for NeuroKaire
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuroKaire
NeuroKaire was founded in 2017 and raised its 1st funding round 1 year after it was founded.
NeuroKaire is headquartered in Kearny, United States. It is registered at Kearny, New Jersey, United States.
Talia Cohen Solal is the current CEO of NeuroKaire. They have also founded this company.
NeuroKaire is a funded company, having raised a total of $20M across 6 funding rounds to date.
NeuroKaire was founded in 2017 in Kearny, United States, within the health technology sector focused on central nervous system disorders. A platform is operated to provide personalized treatments for psychiatric and neurological conditions. Stem cell technology, RNA expression, neurobiology, and artificial intelligence are leveraged to support precision medicine. Optimal medications for patients with depression are predicted using a blood test and questionnaire, with operations centered in the United States.
NeuroKaire's top competitors include Brain.Space, RetiSpec and NeuroXess.
NeuroKaire offers AI Precision Platform and Drug Development Service.
NeuroKaire has 8 investors. Key investors include European Union, GreyBird Ventures, Meron Capital, Jumpspeed, and Sapir Venture Partners.